Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Suggests Supplement Firms Use MedDRA Internally For AER Data

This article was originally published in The Tan Sheet

Executive Summary

FDA suggests supplement firms keep internal records of adverse event data with the same coding system for medical conditions and symptoms that the agency uses
Advertisement

Related Content

Herbalife's Frankos Sees GMP Challenges In New Light After Leaving FDA
Herbalife's Frankos Sees GMP Challenges In New Light After Leaving FDA
FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action
FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action
FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action
Hydroxycut Recall Eyed As Trigger For Closer Look At Supplement AERs
Hydroxycut Recall Eyed As Trigger For Closer Look At Supplement AERs
Advertisement
UsernamePublicRestriction

Register

PS103681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel